Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stock Watch: Queasiness After The Humira Banquet

AbbVie Is Not The Only Company To Suffer

Executive Summary

The second week of first-quarter earnings featured AbbVie’s announcement and a harsh stock price reaction. There were also far-reaching implications behind the results.

You may also be interested in...

Stock Watch: Novartis Earnings Get Interesting Boost

A number of facets from last quarter’s earnings season carried over to Novartis’s first-quarter report, including pipeline attrition and the dependence of sales growth on a single product. While new, still minor products are hoped eventually to buffer its patent expiries, help from another corner has emerged.

Amgen Falters In Core Immunology Business, But Help Is On The Horizon

Sales of Amgen’s key immunology drugs Otezla and Enbrel plunged in Q1, impacted by inventory and competition, but the company will add a new blockbuster when its Horizon acquisition closes in June. 

Stock Watch: J&J’s Q1 Earnings Untroubled By The IRA

J&J’s Q1 earnings announcement included challenges like the loss of exclusivity and competitive pressures, but the price renegotiation associated with the Inflation Reduction Act was not among them.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts